The BCR/ABL1 Quant™ test is a quantitative in vitro diagnostic product to monitor the BCR-ABL1 to ABL1 ratio by RT-qPCR on whole blood of diagnosed Ph+ CML patients expressing e13a2, e14a2 or e1a2 fusion transcripts as an aid in the assessment of complete cytogenetic response, major molecular response, minimal residual disease and relapse.

The test starts with total RNA in a reverse transcription (RT), followed by multiplex real-time quantitative PCR (qPCR) amplification and quantification of BCR-ABL1 (e13a2, e14a2 and e1a2) fusion transcripts and the ABL1 transcript.

Theradiag also offer RNA calibrators for the standardization of the BCR/ABL1 quantification assays. These 4 calibrators are distributed on 5 logs for a better estimation of the major molecular response.